Cytoxan

(cyclophosphamide)

ApprovedSmall molecule

Cyclophosphamide is a chemotherapy drug used to treat various cancers including lymphomas and leukemias, and is also used to treat certain autoimmune diseases like lupus and rheumatoid arthritis by suppressing the immune system.[2] Cytoxan is currently approved and in use across 385 indications[4].[1]

Cytoxan is one of 2675 small molecule programs targeting Leukemia. It is currently in Approved.

385

Indications

3,034

Total Trials

Active Trials

2,674

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

LeukemiaCompleted

Hematopoietic and Lymphoid Cell NeoplasmCompleted

Lung CancerCompleted

RhabdomyosarcomaActive, not recruiting

Ovarian CancerCompleted

Diffuse Large B-Cell LymphomaTerminated

Breast CarcinomaCompleted

T-Cell Acute Lymphoblastic LeukemiaTerminated

Malignant GliomaCompleted

Autoimmune DiseaseEnrolling by invitation

LeukemiaPhase 3

Completed

Hematopoietic and Lymphoid Cell NeoplasmApproved

Completed

Lung CancerPhase 3

Completed

RhabdomyosarcomaPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Completed

Diffuse Large B-Cell LymphomaPhase 3

Terminated

Breast CarcinomaApproved

Completed

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Terminated

Malignant GliomaPhase 2

Completed

Autoimmune DiseasePhase 1

Enrolling by invitation

Showing 10 of 384 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Adenocard

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

2 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Study completion

NCT03983850

Phase 3Active, not recruiting

Triple-Negative Breast Cancer

NCT02488967

Phase 2Recruiting

Immunotherapy

NCT05645380

Phase 2/3Active, not recruiting

Breast Cancer

NCT04290793

Phase 1/2Recruiting

Brain Cancer

NCT06640582

Phase 1/2Recruiting

Advanced/metastatic Solid Tumors

NCT05693844

Clinical

Trials by Indication[1]

Breast Cancer29 trials

Phase II Neoadjuvant in Inflammatory Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00756470·15 enrolled

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Unknown status·XXijing Hospital·Phase 2·NCT03273595·100 enrolled

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Unknown status·IInstituto Nacional de Cancerologia, Columbia·Phase 2·NCT00533936·160 enrolled

Show 26 more trials

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Completed·—·Phase 2·NCT00007904·16 enrolled

The p53 Breast Cancer Trial

Active, not recruiting·HHaukeland University Hospital·Phase 2·NCT02965950·190 enrolled

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02215876

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Terminated·—·Phase 2·NCT00925652·55 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981014·196 enrolled

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00004174·30 enrolled

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

Unknown status·IInstitut Bergonié·Phase 1/2·NCT02630368·197 enrolled

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00971737·63 enrolled

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00016406·399 enrolled

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Unknown status·NNSABP Foundation Inc·Phase 3·NCT00486668·529 enrolled

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Unknown status·AAzienda Ospedaliero-Universitaria di Modena·Phase 3·NCT00629278·2,500 enrolled

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active, not recruiting·HHebei Medical University Fourth Hospital·Phase 2/3·NCT04290793·113 enrolled

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Completed·—·Phase 1·NCT00976131·7 enrolled

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Active, not recruiting·FFudan University·Phase 3·NCT04193059·1,560 enrolled

Preoperative Herceptin and Navelbine for Breast Cancer

Completed·—·Phase 2·NCT00148681·49 enrolled

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 3·NCT02032277·634 enrolled

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Completed·GGrand Hôpital de Charleroi·Phase 1/2·NCT03356860·57 enrolled

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT00033683

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Completed·YYale University·Phase 2·NCT00002679·89 enrolled

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Completed·UUNICANCER·Phase 3·NCT00055679·1,512 enrolled

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT00301925·4,400 enrolled

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03493854·500 enrolled

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00429299·121 enrolled

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy

Completed·GGBG Forschungs GmbH·Phase 2·NCT01594177·65 enrolled

Lymphoma23 trials

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00451178·101 enrolled

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled

Show 20 more trials

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00217503·15 enrolled

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Completed·WWeill Medical College of Cornell University·Phase 1·NCT03036904·31 enrolled

Auto Stem Cell Transplant for Lymphoma Patients

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03125642·150 enrolled

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Withdrawn·AAIDS Malignancy Consortium·Phase 2·NCT00024128

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002757·1,148 enrolled

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00055640·9 enrolled

Stage I/II Nasal NK Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01321008·1 enrolled

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00238368·59 enrolled

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000689·18 enrolled

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00073918·111 enrolled

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Phase 3·NCT05605899·300 enrolled

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT03105336·159 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01026220·166 enrolled

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT01992653·85 enrolled

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00265889·42 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Unknown status·CCentro di Riferimento Oncologico - Aviano·Phase 2·NCT00002905·20 enrolled

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Unknown status·UUnited Kingdom Children's Cancer Study Group·Phase 3·NCT00003423·100 enrolled

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002565·61 enrolled

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00049439·54 enrolled

Chronic Lymphocytic Leukemia10 trials

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01253460·18 enrolled

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02153580·37 enrolled

High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00002788·15 enrolled

Show 7 more trials

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01008462·16 enrolled

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017108

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Completed· Roche logo

Roche·Phase 1·NCT01300247·41 enrolled

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003658·60 enrolled

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00769522·564 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01027000·68 enrolled

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01416974·13 enrolled

Acute Lymphoblastic Leukemia10 trials

Influence of Timing PTCy in AlloSCT

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT05886335·180 enrolled

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Withdrawn·JJuventas Cell Therapy Ltd.·Phase 1/2·NCT06009107

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Recruiting·NNational Hospital Organization Nagoya Medical Center·Phase 2·NCT03286634·60 enrolled

Show 7 more trials

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01690520·163 enrolled

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT05453500·30 enrolled

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01363128·72 enrolled

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00558519·318 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed·GGoethe University·Phase 4·NCT00199069·720 enrolled

Multiple Myeloma9 trials

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·AAjai Chari·Phase 2·NCT02176213·35 enrolled

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00908232·163 enrolled

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Completed·SStanford University·Phase 2·NCT00349778·102 enrolled

Show 6 more trials

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005987·87 enrolled

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Withdrawn·—·Phase 1/2·NCT03100877

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Completed·MMargarida Magalhaes-Silverman·Phase 2·NCT01849783·41 enrolled

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028886·450 enrolled

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Active, not recruiting·MMayo Clinic·Phase 1·NCT05411497·5 enrolled

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02447055

84 more indications

Leukemia6 trials

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Completed·EEmory University·Phase 1·NCT03328104·8 enrolled

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00669877·56 enrolled

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

Show 3 more trials

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002812·2,078 enrolled

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00039130·105 enrolled

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00002531

Metastatic Melanoma4 trials

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00923195·4 enrolled

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00062036·33 enrolled

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

No longer available·FFred Hutchinson Cancer Center··NCT01005537

Show 1 more trial

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT01236573·34 enrolled

Neuroblastoma4 trials

Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma

Completed·SSociete Internationale d'Oncologie Pediatrique·Phase 3·NCT00025428·100 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00567567·665 enrolled

Show 1 more trial

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Unknown status·SSamsung Medical Center·Phase 2·NCT03061656·40 enrolled

Mantle Cell Lymphoma3 trials

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00581776·30 enrolled

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00020943·79 enrolled

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

Completed· Gilead logo

Gilead·Phase 2·NCT02601313·105 enrolled

Pancreatic Cancer3 trials

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00305760·60 enrolled

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03586869·3 enrolled

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

Completed·AAduro Biotech, Inc.·Phase 2·NCT01417000·93 enrolled

Triple-Negative Breast Cancer3 trials

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05872412·82 enrolled

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting·NNRG Oncology·Phase 3·NCT02488967·782 enrolled

Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

Unknown status·TThe Netherlands Cancer Institute·Phase 2·NCT02499367·84 enrolled

Advanced Solid Tumors3 trials

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated·FFate Therapeutics·Phase 1·NCT05395052·5 enrolled

Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

Completed·BBGI, China·Phase 1·NCT02959905·11 enrolled

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Not yet recruiting·FFujian Cancer Hospital·Phase 1·NCT05648994·30 enrolled

Bone Marrow Transplantation3 trials

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002634·45 enrolled

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01350245·28 enrolled

Bone Marrow Transplantation in Treating Patients With Leukemia

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 3·NCT00006451

Prevention2 trials

Haplo Peripheral Blood Sct In GVHD Prevention

Completed·ZZachariah Michael DeFilipp·Phase 1·NCT04473911·25 enrolled

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 2·NCT06550141·28 enrolled

Transplantation2 trials

Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation

Unknown status·SSheba Medical Center·Phase 2·NCT03357159·30 enrolled

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT03246906·150 enrolled

Hematologic Cancer2 trials

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00602693·41 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003270·20 enrolled

Stem Cell Transplantation2 trials

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Completed·CChildren's Oncology Group·Phase 3·NCT00002610·203 enrolled

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

Terminated·NNew York Medical College·Phase 1·NCT00669890·12 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00242996·44 enrolled

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01334502·26 enrolled

Advanced/Metastatic Solid Tumors2 trials

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Not yet recruiting·—·Phase 1/2·NCT06939270·30 enrolled

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05693844·15 enrolled

Chemotherapy2 trials

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003549·80 enrolled

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01341496·41 enrolled

Malignant Glioma2 trials

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008008·40 enrolled

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Completed·—·Phase 2·NCT00047281

Hematologic Malignancies2 trials

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT06343376·1 enrolled

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Completed·SSumithira Vasu·Phase 1·NCT02122081·33 enrolled

Follicular Lymphoma2 trials

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06474481·30 enrolled

Acute Leukemia2 trials

Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

Terminated·MMedical College of Wisconsin·Phase 2·NCT02349178·6 enrolled

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00852709·35 enrolled

Immunotherapy2 trials

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02280811·12 enrolled

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT05645380·139 enrolled

Nasopharyngeal Carcinoma1 trial

Cyclophosphamide for Nasopharyngeal Carcinoma

Completed·TThe University of Hong Kong·Phase 2·NCT02794077·56 enrolled

Adjuvant Treatment1 trial

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309569·429 enrolled

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Unknown status·FFundamenta Therapeutics, Ltd.·Phase 1·NCT05576181·19 enrolled

Ovarian Cancer1 trial

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00652899·14 enrolled

Refractory AML1 trial

T-Cell Depleted Double UCB for Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01464359·3 enrolled

Non-malignant Disorders1 trial

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Terminated·—·Phase 1/2·NCT00801931·1 enrolled

Neoadjuvant Treatment1 trial

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00841828·102 enrolled

Adult ALL1 trial

ALL Adult Consortium Trial: Adult ALL Trial

Completed·—·Phase 2·NCT00476190·112 enrolled

Phase 11 trial

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

Recruiting·TTriArm Therapeutics (Taiwan) Limited·Phase 1·NCT07066397·12 enrolled

Germ Cell Tumor1 trial

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00085098·24 enrolled

Acute Myeloid Leukemia1 trial

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Terminated·CCelularity Incorporated·Phase 1·NCT02781467·10 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01982682·41 enrolled

Tolerance1 trial

Delayed Tolerance Through Mixed Chimerism

Active, not recruiting·MMassachusetts General Hospital·Phase 1/2·NCT05900401·20 enrolled

Completed·CChildren's Oncology Group·Phase 3·NCT00653068·70 enrolled

Autoimmune Disorders1 trial

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06434363·47 enrolled

Multiple Sclerosis1 trial

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

Completed·—·Phase 1·NCT00017628·20 enrolled

B-cell Malignancies1 trial

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Unknown status·SShenzhen Second People's Hospital·Phase 1·NCT02456350·36 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02460588·120 enrolled

Central Nervous System Cancer1 trial

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007982·30 enrolled

Aplastic Anemia1 trial

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2/3·NCT00003816·361 enrolled

Solid Tumors1 trial

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Completed·GGenexine, Inc.·Phase 1·NCT03733587·24 enrolled

Medulloblastoma1 trial

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT02017964·26 enrolled

Pembrolizumab1 trial

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Active, not recruiting·IImmunoVaccine Technologies, Inc. (IMV Inc.)·Phase 2·NCT03836352·184 enrolled

DLBCL1 trial

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Completed· Roche logo

Roche·Phase 3·NCT02406092·139 enrolled

Conditioning1 trial

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Completed·SSangamo Therapeutics·Phase 1/2·NCT02225665·8 enrolled

CAR-T1 trial

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Suspended·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT04855253·30 enrolled

Hematopoietic Cell Transplantation (HCT)1 trial

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Completed·—·Phase 1·NCT02167958·28 enrolled

Dendritic Cell1 trial

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Completed·UUniversity of Arkansas·Phase 2·NCT00083538·40 enrolled

Gastroesophageal Junction Cancer1 trial

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Completed·—·Phase 1/2·NCT03918499·9 enrolled

Anemia1 trial

Haploidentical PBMC Transplant for Severe Congenital Anemias

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00977691·23 enrolled

Efficacy and Safety1 trial

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Advanced Malignancies1 trial

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02419495·221 enrolled

Primary Systemic Amyloidosis1 trial

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Completed·MMayo Clinic·Phase 2·NCT00564889·35 enrolled

Small Cell Lung Cancer1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00002858·280 enrolled

Advanced1 trial

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting·TTCR2 Therapeutics·Phase 1/2·NCT03907852·57 enrolled

Stem Cell1 trial

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02220985·84 enrolled

Chronic Granulomatous Disease1 trial

Completed·—·Phase 2·NCT00578643·15 enrolled

Nausea and vomiting1 trial

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Completed·UUniversity of Washington·N/A·NCT00343863·41 enrolled

Allogeneic Stem Cell Transplantation1 trial

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Completed·—·Phase 2/3·NCT01019876·38 enrolled

Myelodysplastic Syndrome1 trial

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated·WWashington University School of Medicine·Phase 1/2·NCT01898793·89 enrolled

Soft Tissue Sarcoma1 trial

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT04052334·9 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Brain Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Recruiting·EEssen Biotech·Phase 1/2·NCT06640582·85 enrolled

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia

Unknown status·IIII. Medizinische Klinik Mannheim·Phase 3·NCT00025402·1,000 enrolled

Melanoma1 trial

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01495572·5 enrolled

Patients With Solid Tumors1 trial

HER2-Peptide Vaccination of Patients With Solid Tumors

Completed·TTechnical University of Munich·Phase 1·NCT02276300·2 enrolled

T-cell acute lymphoblastic leukemia1 trial

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03384654·47 enrolled

Lymphoblastic Lymphoma1 trial

Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Terminated·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00275106·600 enrolled

Henoch-Schoenlein purpura1 trial

Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT00190229·200 enrolled

Advanced Refractory Solid Tumors1 trial

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT03171220·40 enrolled

Metastatic Cancer1 trial

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT02153905·3 enrolled

Papilloma1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01585428·29 enrolled

Thalassemia1 trial

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Terminated·—·N/A·NCT00578292·10 enrolled

Advanced Hematologic Malignancies1 trial

FT538 in Subjects With Advanced Hematologic Malignancies

Terminated·FFate Therapeutics·Phase 1·NCT04614636·42 enrolled

Relapsed/Refractory Hematological Malignancies1 trial

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Recruiting·—·Phase 1·NCT05528887·10 enrolled

Hepatocellular Carcinoma1 trial

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03563170

Autologous Stem Cell Transplantation1 trial

Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting·PPaul Szabolcs·Phase 1/2·NCT00692939·20 enrolled

Immunodeficiency1 trial

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00358657·14 enrolled

Hematopoietic Stem Cell Transplant1 trial

Hematopoietic Stem Cell Transplant in Devic's Disease

Completed·NNorthwestern University·Phase 1/2·NCT00787722·13 enrolled

AL amyloidosis1 trial

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT00607581·21 enrolled

Unspecified3 trials

Optimizing PTCy Dose and Timing

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT03983850·105 enrolled

Cabozantinib With Topotecan-Cyclophosphamide

Completed·—·Phase 1·NCT04661852·12 enrolled

Velcade (Bortezomib) Consolidation After Transplant

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01539083·256 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

CYTOXAN

NDA NDA012142

Jan 1, 1982

CYTOXAN

NDA NDA012141

Sep 16, 2013

CYCLOPHOSPHAMIDE

NDA NDA203856

Jul 30, 2020

CYCLOPHOSPHAMIDE

NDA NDA212501

Aug 25, 2021

CYCLOPHOSPHAMIDE

NDA NDA210735

Jun 7, 2023

FRINDOVYX

NDA NDA210852

Jun 28, 2023

CYCLOPHOSPHAMIDE

NDA NDA217651

Sep 12, 2023

CYCLOPHOSPHAMIDE

NDA NDA217150

Sources

References

[1]
ClinicalTrials.gov — 3034 trial records for cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cytoxan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217150). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Cytoxan. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Patent Landscape[6]

Patent Cliff

Jun 26, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9662342Jun 26, 2035

10849916Jul 13, 2035

11382923Dec 1, 2035

12329767Feb 15, 2036

10993952Feb 15, 2036

Cytoxan

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer29 trials

Lymphoma23 trials

Chronic Lymphocytic Leukemia10 trials

Acute Lymphoblastic Leukemia10 trials

Multiple Myeloma9 trials

Leukemia6 trials

Metastatic Melanoma4 trials

Neuroblastoma4 trials

Mantle Cell Lymphoma3 trials

Pancreatic Cancer3 trials

Triple-Negative Breast Cancer3 trials

Advanced Solid Tumors3 trials

Bone Marrow Transplantation3 trials

Prevention2 trials

Transplantation2 trials

Hematologic Cancer2 trials

Stem Cell Transplantation2 trials

Diffuse Large B-Cell Lymphoma2 trials

Advanced/Metastatic Solid Tumors2 trials

Chemotherapy2 trials

Malignant Glioma2 trials

Hematologic Malignancies2 trials

Follicular Lymphoma2 trials

Acute Leukemia2 trials

Immunotherapy2 trials

Nasopharyngeal Carcinoma1 trial

Adjuvant Treatment1 trial

B-cell acute lymphoblastic leukemia1 trial

Ovarian Cancer1 trial

Refractory AML1 trial

Non-malignant Disorders1 trial

Neoadjuvant Treatment1 trial

Adult ALL1 trial

Phase 11 trial

Germ Cell Tumor1 trial

Acute Myeloid Leukemia1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Tolerance1 trial

Scleroderma1 trial

Adenocarcinoma1 trial

Atypical Teratoid/Rhabdoid Tumor1 trial

Autoimmune Disorders1 trial

Multiple Sclerosis1 trial

B-cell Malignancies1 trial

Idiopathic Pulmonary Fibrosis1 trial

Central Nervous System Cancer1 trial

Aplastic Anemia1 trial

Solid Tumors1 trial

Medulloblastoma1 trial

Pembrolizumab1 trial

DLBCL1 trial

Conditioning1 trial

CAR-T1 trial

Hematopoietic Cell Transplantation (HCT)1 trial

Dendritic Cell1 trial

Gastroesophageal Junction Cancer1 trial

Anemia1 trial

Efficacy and Safety1 trial

Advanced Malignancies1 trial

Primary Systemic Amyloidosis1 trial

Small Cell Lung Cancer1 trial

Advanced1 trial

Stem Cell1 trial

Chronic Granulomatous Disease1 trial

Nausea and vomiting1 trial

Allogeneic Stem Cell Transplantation1 trial

Myelodysplastic Syndrome1 trial

Soft Tissue Sarcoma1 trial

Urothelial Cancer1 trial

Brain Cancer1 trial

Rhabdomyosarcoma1 trial

Chronic Myelogenous Leukemia1 trial

Melanoma1 trial

Patients With Solid Tumors1 trial